Nativa won a patent dispute with Bristol-Myers Squibb with regard to dasatinib

| By | Bristol-Myers Squibb, Drug Patents, Import Substitution, Nativa

The Arbitration Court of the Moscow region decided to fully reject the claims filed by Bristol-Myers Squibb Holdings Ireland against Nativa LLC under the case No. A41-87845/2017.

In October 2017, Bristol-Myers Squibb Holdings Ireland filed a lawsuit against the Russian manufacturer to prevent the threat of patent infringement by imposing an injunction on the introduction of drug into civil circulation. The drug in question was dasatinib-nativ (INN: dasatinib) intended for the treatment of chronic myeloid leukemia.

The Arbitration Court did not find any violation of foreign company’s exclusive rights in the actions of defendant and, as a result, decided to fully reject the claims.

Nativa is involved in litigation on a number of patent disputes with the largest multinational companies. It has already won 6 of them.

The head of the company said that the actions of foreign corporations no longer have such a “crushing” power as in the past.

“National manufacturers have substantially strengthened their positions in Russia. We feel strong assistance and real support from the state,” said Mr. Malin.

GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.